Loading...

Basilea Pharmaceutica AG

0QNA.L•LSE
Healthcare
Medical - Pharmaceuticals
£48.10
£0.90(1.91%)

Basilea Pharmaceutica AG (0QNA.L) Stock Overview

Explore Basilea Pharmaceutica AG’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 73.0/100

Key Financials

Market Cap589M
P/E Ratio8.41
EPS (TTM)$-0.58
ROE1.59%
Fundamental Analysis

AI Price Forecasts

1 Week$48.13
1 Month$45.61
3 Months$50.08
1 Year Target$40.17

0QNA.L Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Basilea Pharmaceutica AG (0QNA.L) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 53.60, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $40.17.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 8.41 and a market capitalization of 589M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

53.60RSI (14)
0.00MACD
21.70ADX
Stats data is not available for 0QNA.LStats details for 0QNA.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for 0QNA.LAnalyst Recommendations details for 0QNA.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing Derazantinib, a small molecule inhibitor, which is in phase 2 clinical trial for bile duct cancer, as well as in phase ½ clinical trial for bladder and stomach cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.

CEO

David Veitch

Employees

164

Headquarters

Grenzacherstrasse 487, Allschwil

Founded

2014

Frequently Asked Questions

;